Translate Bio enters manufacturing agreement with AMRI for mRNA capabilities
Translate Bio announced that it has entered into a multi-year strategic manufacturing agreement with Albany Molecular Research, or AMRI, a global clinical development manufacturing organization, in support of the planned expansion of Translate Bio's current good manufacturing practices, or cGMP, clinical mRNA manufacturing capabilities. Under the five-year agreement, AMRI will build out new, dedicated cGMP clinical manufacturing suites that will support Translate Bio's manufacturing needs. This allows for control and access to AMRI's cGMP manufacturing capacity and experience to advance Translate Bio's preclinical and clinical-stage programs. Translate Bio's lead program is an inhaled mRNA therapeutic in an ongoing Phase 1/2 clinical trial in patients with cystic fibrosis. Its preclinical programs are focused primarily on targets in additional pulmonary diseases and also include infectious disease targets for vaccine applications. Other discovery efforts include next-generation delivery programs for applications in diseases that affect the liver.